» Articles » PMID: 33240635

The Optimal Platelet Concentration in Platelet-rich Plasma for Proliferation of Human Cells in Vitro-diversity, Biases, and Possible Basic Experimental Principles for Further Research in the Field: A Review

Overview
Journal PeerJ
Date 2020 Nov 26
PMID 33240635
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In the last decades, several in vitro studies have tested the effect of plate-rich plasma (PRP) on the proliferation of human cells in search of a wizard for the use of PRP in a clinical setting. However, the literature displays striking differences regarding this question despite the relatively similar experimental design. The aim of this review is twofold: describe and explain this diversity and suggest basic principles for further in vitro studies in the field. The optimal platelet concentration in vivo will also be discussed.

Methods: A search in mainly EMBASE and PubMed was performed to identify in vitro studies that investigate the effect of different PRP concentrations on human cell proliferation. The assessment of bias was based on the principles of "Good Cell Culture Practice" and adapted.

Results: In total, 965 in vitro studies were detected. After the initial screening, 31 studies remained for full-text screening. A total of 16 studies met the criteria of final inclusion and appeared relatively sound. In general, the studies state consistently that PRP stimulates the proliferation of the human cell. Two main types of experimental techniques were detected: 1. using a fixed PRP concentration throughout the experiment, which leads to a substantial decrease in nutrition available at higher concentrations. 2. using a fixed PRP-to-media ratio (Vol/Vol) throughout the experiment. A general tendency was observed in both groups: when the PRP to media ratio increased (Vol/Vol), the proliferation rate decreased. Further, observed a substantial higher optimal PRP concentration than . No prominent tendencies was seen regarding anticoagulants, activation methods, and blood donor (age or sex).

Discussion: Two major biases regarding optimal proliferation in vitro is pointed out: . It is speculated that the techniques used by some studies led to an adverse growth condition and even cell starvation at higher concentrations. Reduced proliferation rate due to proinflammatory substances released during degranulation of leukocytes.

Conclusions: The two main biases may explain the bell-shaped effect of PRP and the detrimental effects at higher platelet concentrations observed in several studies. These biases may also explain the low optimal PRP concentration observed in some studies. Even if one universal optimal PRP concentration does not exist, the review indicates that PRP concentrations in the upper parts of the scale is optimal or at least beneficial. Finally, following basic experimental principles are suggested. 1: The PRP/media ratio (Vol/Vol) should be kept as constant. 2: The PRP/media ratio should provide a sufficient nutrition supply, that is, PRP ≤ 10% (Vol/Vol). 3: The cell density per well (cells/mL) should be defined. 4: Leukocyte level should be kept low, preferable depleted (< 0.1 PLT/µL).

Citing Articles

Platelet-Rich Plasma Inhibits Breast Cancer Proliferation.

Han C, Chen C, Lu N, Xue L, Xing D, Wu W Clin Med Insights Oncol. 2024; 18:11795549241298978.

PMID: 39555114 PMC: 11569502. DOI: 10.1177/11795549241298978.


Current Challenges in the Development of Platelet-Rich Plasma-Based Therapies.

Mercader-Ruiz J, Beitia M, Delgado D, Sanchez P, Porras B, Gimeno I Biomed Res Int. 2024; 2024:6444120.

PMID: 39157212 PMC: 11329313. DOI: 10.1155/2024/6444120.


Navigating the Therapeutic Landscape: A Comprehensive Review of Platelet-Rich Plasma and Bone Marrow Aspirate Concentrate in Knee Osteoarthritis.

Balusani Jr P, Shrivastava S, Pundkar A, Kale P Cureus. 2024; 16(2):e54747.

PMID: 38524005 PMC: 10960965. DOI: 10.7759/cureus.54747.


Advances with Platelet-Rich Plasma for Bone Healing.

Bacevich B, Smith R, Reihl A, Mazzocca A, Hutchinson I Biologics. 2024; 18:29-59.

PMID: 38299120 PMC: 10827634. DOI: 10.2147/BTT.S290341.


The Tumor Necrosis Factor-α Level in Platelet-Rich Plasma Might Be Associated with Treatment Outcome in Patients with Interstitial Cystitis/Bladder Pain Syndrome or Recurrent Urinary Tract Infection.

Jhang J, Jiang Y, Lin T, Kuo H Int J Mol Sci. 2024; 25(1).

PMID: 38203334 PMC: 10779330. DOI: 10.3390/ijms25010163.


References
1.
Kumaran M . Platelet-rich plasma in dermatology: boon or a bane?. Indian J Dermatol Venereol Leprol. 2014; 80(1):5-14. DOI: 10.4103/0378-6323.125467. View

2.
Cervelli V, Scioli M, Gentile P, Doldo E, Bonanno E, Spagnoli L . Platelet-rich plasma greatly potentiates insulin-induced adipogenic differentiation of human adipose-derived stem cells through a serine/threonine kinase Akt-dependent mechanism and promotes clinical fat graft maintenance. Stem Cells Transl Med. 2012; 1(3):206-20. PMC: 3659852. DOI: 10.5966/sctm.2011-0052. View

3.
Liu Y, Zhou Y, Feng H, Ma G, Ni Y . Injectable tissue-engineered bone composed of human adipose-derived stromal cells and platelet-rich plasma. Biomaterials. 2008; 29(23):3338-45. DOI: 10.1016/j.biomaterials.2008.04.037. View

4.
Engebretsen L, Steffen K, Alsousou J, Anitua E, Bachl N, Devilee R . IOC consensus paper on the use of platelet-rich plasma in sports medicine. Br J Sports Med. 2010; 44(15):1072-81. DOI: 10.1136/bjsm.2010.079822. View

5.
Mishra A, Tummala P, King A, Lee B, Kraus M, Tse V . Buffered platelet-rich plasma enhances mesenchymal stem cell proliferation and chondrogenic differentiation. Tissue Eng Part C Methods. 2009; 15(3):431-5. PMC: 2819709. DOI: 10.1089/ten.tec.2008.0534. View